Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

Published:2009-05 Issue:1 Volume:51 Page:29-36
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Mallolas Josep,Podzamczer Daniel,Milinkovic Ana,Domingo Pere,Clotet Bonaventura,Ribera Esteve,Gutiérrez Félix,Knobel Hernando,Cosin Jaime,Ferrer Elena,Arranz José Alberto,Roca Victor,Vidal Francesc,Murillas Javier,Pich Judit,Pedrol Enric,Llibre Josep M,Dalmau David,García Isabel,Aranda Miquel,Cruceta Ana,Martínez Esteban,Blanco José L,Lazzari Elisa de,Gatell José M

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference15 articles.

1. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice.;Stone;Clin Infect Dis,2001

2. Adherence to HAART regimens.;Chesney;AIDS Patient Care STDS,2003

3. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients.;Scott;Am J Health Syst Pharm,2005

4. Metabolic issues associated with protease inhibitors.;Moyle;J Acquir Immune Defic Syndr,2007

5. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.;Gatell;Clin Infect Dis,2007

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV and Dyslipidemia;Contemporary Cardiology;2020-12-16

2. Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis;African Health Sciences;2020-04-20

3. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV;The Journal of Infectious Diseases;2019-12-11

4. Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs;Journal of the International Association of Providers of AIDS Care (JIAPAC);2019-01-01

5. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients;PLOS ONE;2018-09-20